Related by context. All words. (Click for frequent words.) 67 locoregional recurrence 67 pT3 67 pT2 66 completely resected 66 intravesical therapy 65 histologic subtype 65 lymphovascular invasion 65 urothelial carcinoma 65 grade cervical intraepithelial 65 HGPIN 65 mucinous 65 histological subtype 65 thyroglobulin 65 liver metastasis 65 epithelial tumors 64 sonographically guided 64 follicular thyroid cancer 64 CIN2 + 64 HER2 expression 64 transabdominal 64 seminal vesicle invasion 64 5alpha reductase 64 TMPRSS2 ERG 64 PCa 64 hamartomas 63 prostate carcinoma 63 AST ALT 63 breast carcinomas 63 extracapsular extension 63 papillary thyroid carcinoma 63 biochemical recurrence 63 sarcomatoid 63 haematologic 63 radiotherapy RT 63 radical prostatectomy RP 63 T1c 63 lymphadenectomy 63 tumor histology 63 prognostic biomarker 63 hormone receptor negative 63 Papillary 63 intact parathyroid hormone 63 colorectal adenoma 63 clinicopathological 62 epoetin alpha 62 thyroid carcinoma 62 CLL SLL 62 endocervical 62 renal tumors 62 TRAIL R1 62 FDG PET imaging 62 aminotransferase 62 micrometastasis 62 endometrioid 62 carcinoembryonic antigen 62 autologous SCT 62 Ki# 62 Immunohistochemical staining 62 lymph node metastasis 62 FDG uptake 62 pituitary adenomas 62 liposomal amphotericin B 62 Histologic 62 metastatic lymph nodes 62 prostate cancer CaP 62 urine cytology 62 intraepithelial neoplasia 62 CaP 62 microsatellite instability 62 papillary renal cell carcinoma 61 invasive ductal 61 progesterone receptor 61 advanced adenoma 61 carcinoids 61 clinicopathological features 61 F FDG PET 61 K ras mutations 61 neoplasms 61 hMG 61 leiomyomas 61 scintigraphic 61 cTnI 61 tumoral 61 gastric adenocarcinoma 61 prognostic significance 61 biopsy Gleason 61 HNSCC 61 invasive carcinomas 61 hyperoxaluria 61 KRAS mutation 61 hematological parameters 61 non squamous histology 61 bronchioloalveolar carcinoma 61 imiquimod cream 61 clinicopathologic 61 ultrasonographic 61 metastatic malignant 61 papillary 61 renal pelvis 61 sonographically 61 squamous 61 biliary tract cancer 61 -#.# ± [002] 61 relapsed MM 61 esophageal carcinoma 61 TRUS 61 histologic 61 NSCLC tumors 61 debulking surgery 61 colorectal liver metastases 61 breast carcinoma 61 advanced adenomas 61 pharmacodynamic biomarkers 61 thrombogenic 61 cytologic examination 61 malignant nodules 61 immunostaining 61 preoperative PSA 61 transrectal ultrasound guided 61 resectable 60 osteosarcomas 60 pCR 60 renal cell carcinomas 60 extracranial 60 prognostic indicators 60 undetectable HBV DNA 60 bronchoalveolar lavage 60 underwent surgical resection 60 tumor necrosis 60 immunohistochemical analysis 60 ovarian carcinoma 60 extranodal 60 heparanase 60 seminomas 60 adjuvant radiotherapy 60 polyp recurrence 60 HER2 amplification 60 demonstrated antitumor activity 60 SLNB 60 gastric carcinoma 60 cystectomy 60 antiproliferative effects 60 Leydig cell 60 lymph node metastases 60 histologic subtypes 60 EBUS FNA 60 prostate cancer PCa 60 EUS FNA 60 differentiated thyroid 60 unresectable tumors 60 TIMP 60 myeloproliferative diseases 60 adenomatous 60 radiochemotherapy 60 florbetaben 60 antiangiogenic agent 60 % Confidence Interval 60 immunohistochemical 60 neoplasias 60 HERmark assay 60 tumorigenicity 60 pancreatic adenocarcinoma 60 intrahepatic 60 mutated K ras 60 Histological 60 pmol L 60 myeloperoxidase 60 rs# [004] 60 transurethral resection 60 metaplasia 60 cytologic 60 MGd 60 serum PSA 60 p# antigen 60 histopathologic 60 pericardial effusion 60 CRp 60 antitumor effect 60 distant metastasis 60 recurrent glioblastoma multiforme 60 pretransplant 60 Panzem R NCD 60 statistically significant p = 60 mRNA expression 60 ERalpha 60 skeletal metastases 60 TIMP 1 60 adenocarcinomas 60 confidence interval #.#-#.# 60 leukocyte count 60 coronary stenosis 60 intima media thickness 60 BCR ABL mutations 60 PSA nadir 60 busulfan 60 radiosensitivity 59 radical nephrectomy 59 micrometastases 59 malignant ascites 59 p# biomarker 59 hepatocellular carcinomas 59 NMP# 59 annexin 59 histologic findings 59 mTOR inhibition 59 D dimer 59 HER2 ErbB2 59 NMIBC 59 Endometrial 59 prognostically 59 metastatic malignant melanoma 59 localized renal 59 urothelial cancer 59 T1a 59 isoenzyme 59 underwent resection 59 endothelial activation 59 tPSA 59 cytotoxicity assays 59 sorafenib Nexavar 59 mediastinal 59 serum TSH 59 TMPRSS2 ERG fusion 59 galiximab 59 5 Fluorouracil 59 micafungin 59 GISTs 59 response pCR 59 sequence homology 59 surgically resectable 59 pulmonary metastases 59 neoadjuvant 59 cytokeratin 59 histopathological 59 fluoropyrimidine 59 bladder carcinoma 59 immunomodulation 59 antiphospholipid antibodies 59 serum concentrations 59 prognostic indicator 59 HRCT 59 serum prostate 59 malignant lesions 59 Histopathological 59 biochemical relapse 59 urothelial 59 lobular carcinoma 59 cervical carcinoma 59 pheochromocytoma 59 genotypic resistance 59 Taxotere chemotherapy 59 stenoses 59 metastatic RCC 59 nonmetastatic 59 Xelox 59 Nilotinib 59 colorectal carcinoma 59 endometrial carcinoma 59 invasive lobular carcinoma 59 immunochemical fecal occult 59 urothelial bladder cancer 59 assay detects 59 RRM1 59 Estrogen Receptor 59 metastatic renal cell carcinoma 59 #F FDG PET 59 caspofungin 59 taxane therapy 59 gefitinib Iressa 59 PROSTVAC VF 59 multivariable analysis 59 graft occlusion 59 resected tumors 59 HDACi 59 BRAF V#E 59 Plasma concentrations 59 histologies 59 neovascular 59 colorectal adenocarcinoma 59 needle aspiration 59 neutrophil count 59 carotid stenosis 59 cerebrospinal fluid CSF 59 prospectively randomized 59 immunohistochemical staining 59 lymph node involvement 59 hematopoietic cancers 59 multicentric 59 lung carcinomas 59 cytogenetic abnormalities 59 Pharmacokinetics PK 59 promoter methylation 59 follicular lymphoma FL 59 lung pancreatic 59 baseline LDH 59 adrenocortical 59 Doxil ® 59 progesterone receptor negative 59 EpCAM 59 elevated LDH 59 echogenic 59 Bezielle 59 prostatic 59 endoscopic ultrasonography 58 submucosal 58 Solorel TM 58 cisplatin gemcitabine 58 TOP2A 58 postoperative chemotherapy 58 colorectal gastric 58 tryptase 58 PTHrP 58 leiomyoma 58 ASCUS 58 Squamous 58 MAGE A3 ASCI 58 endobronchial 58 histologic examination 58 tumor recurrence 58 lymphocytosis 58 basal cell carcinoma BCC 58 RQ PCR 58 anti angiogenic agents 58 invasive lobular 58 neoplastic 58 hypervascular 58 Upregulation 58 neoadjuvant treatment 58 EBRT 58 antiangiogenic therapy 58 metachronous 58 endometrial hyperplasia 58 prognostic markers 58 nodal metastases 58 B7 H3 58 urography 58 troponin T 58 hepatic enzyme 58 hormone receptor status 58 KRAS mutation status 58 node metastases 58 hepatoma 58 tumor xenograft models 58 lymphoproliferative disorders 58 hemodynamically significant 58 axillary lymph nodes 58 TURBT 58 FOLFOX6 58 rs# [001] 58 CsA 58 fosbretabulin 58 immunohistochemistry IHC 58 concurrent chemoradiation 58 preoperative chemotherapy 58 Squalamine 58 bFGF 58 surgically resected 58 flutamide 58 essential thrombocythemia 58 adenoma recurrence 58 LHRH receptor positive 58 specific antigen PSA 58 receptor inhibitor 58 chemoresistant 58 bovine thrombin 58 neutropaenia 58 cervicovaginal 58 intratumoral 58 aurora kinase 58 superficial femoral 58 INCB# [003] 58 PEG IFN 58 Xanafide 58 â ‰ ¥ 58 chemosensitivity 58 polycythemia vera essential thrombocythemia 58 periprocedural 58 lobular carcinomas 58 P = .# 58 axillary node dissection 58 comparator arm 58 SGPT 58 ABCB1 58 osteoid 58 serum lipid 58 thyroid carcinomas 58 5-FU/LV 58 Allogeneic 58 stage IIIB 58 CIN3 + 58 transitional cell carcinoma 58 allogeneic HSCT 58 Histopathologic 58 pleural fluid 58 antiangiogenic agents 58 thyroid nodules 58 cisplatin resistant 58 gene amplification 58 biodistribution 58 pharmacodynamic markers 58 cardiac perfusion 58 situ CIS 58 para aortic 58 situ LCIS 58 pamidronate 58 vivo potency 58 mesangial 58 hepatic metastases 58 interleukin IL -# 58 achieved statistical significance 58 antitumour activity 58 NEUVENGE 58 transdermal estradiol 58 pancreatic carcinoma 58 IIIb 58 adjuvant radiation 58 osteoblastic 58 58 steroidogenic 58 creatine kinase MB 58 adenomatous polyps 58 pleomorphic 58 Flu Cy 58 thromboembolic disease 58 mammographic density 58 radioimmunotherapy RIT 58 SLN biopsy 58 SUVmax 58 prognostic variables 58 XIENCE V PROMUS Stent 58 androgen independent 58 invasive carcinoma 58 Tarceva TM 58 doxorubicin docetaxel 58 normal karyotype 58 total thyroidectomy 58 hyperplastic polyps 58 operable breast cancer 58 selective modulator 58 tigecycline 58 μg ml 58 Prostatic 58 gemcitabine carboplatin 58 haematological 58 PSA kinetics 58 hypogonadal 58 apolipoproteins 58 antibody titer 58 locoregional 58 seminoma 58 μmol L 58 Genotypes 58 echocardiographic parameters 58 Gram stain 57 lymphadenopathy 57 Adjuvant chemotherapy 57 chemoradiotherapy 57 stage IIIA 57 refractory prostate cancer 57 endometrial adenocarcinoma 57 tissue oxygenation 57 prostaglandin E 57 FDG-PET/CT 57 unfavorable cytogenetics 57 metastatic neuroendocrine tumors 57 HSCT 57 benign neoplasms 57 malignant prostate 57 ErbB2 positive 57 PGDH 57 mRCC 57 kinase inhibition 57 Hurthle cell 57 Oncotype DX Recurrence Score 57 cervical intraepithelial neoplasia 57 gastric cardia 57 carotid IMT 57 estrogen receptor ER 57 renal cysts 57 fine needle aspiration 57 percutaneous biopsy 57 proctitis 57 resected 57 colorectal adenomas 57 KRAS wild 57 pain palliation 57 parenchymal 57 triiodothyronine 57 bioavailable testosterone 57 osteogenic 57 Cystatin C 57 BEXXAR Therapeutic Regimen 57 ductal carcinomas 57 external beam radiotherapy 57 idraparinux 57 immunoreactivity 57 inhibitor COX 57 progesterone receptor PR 57 FISH fluorescence 57 recurrent NSCLC 57 peritoneal carcinomatosis 57 univariate analysis 57 perineural invasion 57 neoadjuvant chemotherapy 57 core needle biopsies 57 targeting CD# 57 cervical lymph node 57 cardiac troponin 57 orally administered inhibitor 57 histopathologic examination 57 Aplidin 57 rs# [002] 57 receptor tyrosine kinase inhibitor 57 Adenomas 57 prostatic tissue 57 KRAS status 57 RezularTM 57 imatinib therapy 57 periprocedural MI 57 mediated inhibition 57 mTOR inhibitors 57 gemcitabine Gemzar 57 Thal Dex 57 peripheral blood mononuclear 57 glutamyl 57 oncologic outcomes 57 distant metastases 57 CR nPR 57 alefacept 57 Immunohistochemistry 57 ALT elevation 57 neoadjuvant therapy 57 refractory chronic lymphocytic 57 breast cancer subtypes 57 choroidal neovascularization 57 urinary N telopeptide 57 CYT# potent vascular disrupting 57 seminal vesicle 57 prospective multicenter study 57 delafloxacin 57 thymectomy 57 metastatic lesions 57 neointimal 57 Immunotherapeutic 57 nodal metastasis 57 histologically confirmed 57 wedge resection 57 #OHD 57 somatic mutations 57 HLA DRB1 * 57 #F FDG 57 myocardial revascularization 57 guaiac 57 prognostic marker 57 WT1 57 SNP rs# [002] 57 STRIDE PD 57 metastatic gastric 57 neoplastic lesions 57 fallopian tube cancers 57 radiographic findings 57 sonographic findings 57 endometrial 57 Surgical resection 57 SOM# 57 dosing cohort 57 severe neutropenia 57 D Dimer 57 IL#B 57 ERBB2 57 immunocytochemistry 57 lymphoid tissue 57 aortic regurgitation 57 lymphoid malignancies 57 clevidipine 57 neoplasia 57 gene polymorphisms 57 tirofiban 57 thiopurine 57 paclitaxel eluting stents 57 lactate dehydrogenase LDH 57 esophageal gastric 57 chromosomal mutations 57 castrate resistant 57 pharmacodynamic PD 57 superficial bladder cancer 57 axillary node 57 mg/m2 dose 57 Hematologic 57 serum urate levels 57 lesional 57 splenic 57 Lenalidomide 57 axillary dissection 57 nonalcoholic steatohepatitis NASH 57 depsipeptide 57 adjuvant therapy 57 cardiac repolarization 57 β blockers 57 renal cortical 57 selective agonists 57 anthracycline containing 57 postmenopausal osteoporotic women 57 tHcy 57 nicardipine 57 mitomycin C 57 prospectively evaluated 57 liposomal formulation 57 patients undergoing CABG 57 adjuvant cisplatin 57 LHRH agonists 57 pharmacodynamic parameters 57 Epidermal Growth Factor Receptor 57 polyposis 57 anti HBs 57 hyperplastic 57 K ras 57 biologic DMARD 57 ADPKD 57 ECOG PS 57 erythropoietic 57 Cardiotoxicity 57 plasma pharmacokinetics 57 intestinal metaplasia 57 vascular disrupting agents 57 SPINK1 57 sitosterol 57 sensitivity specificity 57 sustained virological response 57 miRview squamous 57 AGHD 57 carcinoid tumors 57 % CI #.#-#.# [001] 57 multivariable adjusted 57 NGAL 57 hypointense 56 Achieves Primary Endpoint 56 predictive biomarker 56 overlapping toxicities 56 haematopoietic 56 Preoperative 56 acute GvHD 56 mitomycin 56 CCR9 56 castrate resistant prostate cancer 56 anthracycline taxane 56 tumor lysis syndrome 56 untreated metastatic melanoma 56 T2 lesions 56 bendamustine 56 effector function 56 penetrance 56 hematological relapse 56 splice variants 56 prognostic factor 56 pheochromocytomas 56 tumor subtypes 56 anti CD# antibodies 56 NSABP B 56 allogeneic SCT 56 binary restenosis 56 mesenteric 56 isoprostane 56 mitochondrial toxicity 56 oblimersen 56 pancreatic prostate 56 mmol kg 56 JAK inhibitors 56 alkylating agent 56 Subgroup analysis 56 pegylated liposomal doxorubicin 56 pathologic 56 metastatic liver 56 hydronephrosis 56 constitutively active 56 symptomatic VTE 56 recurrent metastatic 56 fluconazole resistant 56 #m Tc 56 endothelin receptor antagonists 56 interobserver reliability 56 metastatic carcinoma 56 hyperintensity 56 bexarotene 56 neuroendocrine carcinoma 56 HLA DR 56 uM 56 peritoneal fluid 56 ENMD # 56 parathyroid 56 etiologic 56 inhibin B 56 multiple myeloma MM 56 ‰ ¥ 56 EGFR HER2 56 liver histology 56 TP# mutations 56 transthoracic 56 UGT#A# 56 ESR1 56 squamous intraepithelial lesions 56 Stage IIIb 56 cell adhesion molecule 56 Clusterin 56 radical cystectomy 56 humanised monoclonal antibody 56 nanomolar 56 lactate dehydrogenase 56 histologically proven 56 VP# [004] 56 novel histone deacetylase 56 electrophysiologic 56 HepG2 cells 56 intra arterial chemotherapy 56 estrogen receptor progesterone receptor 56 cutaneous melanoma 56 multivariate analyzes 56 cytoreductive surgery 56 neoplasm 56 eTag assays 56 HER2/neu 56 BrachySil TM 56 hematologic toxicity 56 inducible nitric oxide synthase 56 cisplatin vinorelbine 56 artery stenosis 56 severe hypersensitivity reactions 56 Prognostic 56 MALT lymphoma 56 carotid plaque 56 mycosis fungoides 56 BCG refractory 56 antimitotic 56 #ß 56 statistical significance p 56 PITX2 56 Folfox 56 rho = 56 Barrett esophagus BE 56 mononuclear 56 alanine aminotransferase 56 T2 weighted images 56 hematuria 56 ipsilateral breast 56 enterococcal 56 paragangliomas 56 noninferior 56 Leukemias 56 #.#ng/ml 56 CINQUIL 56 preoperative diagnosis 56 stratifying patients 56 small lymphocytic lymphoma 56 corrected QT interval 56 grade squamous intraepithelial 56 eptifibatide 56 pretest probability 56 cranial irradiation 56 hilar 56 cellularity 56 xenograft tumors 56 Angiographic 56 apremilast 56 HER2 receptor 56 excisional biopsy 56 abnormal cytology 56 dysplastic 56 monocyte chemoattractant protein 56 x ULN 56 Epigenomics proprietary 56 Radical prostatectomy 56 glycoprotein IIb IIIa inhibitors 56 gene polymorphism 56 creatinine ratio 56 lymph node dissection 56 cytoreductive nephrectomy 56 aggregated Abeta 56 DLTs 56 HBeAg negative 56 sirolimus stent 56 metastatic GIST 56 HbF 56 HIV HCV coinfected 56 null responder 56 mg p = 56 nonischemic 56 anti CD3 56 malignant neoplasms 56 CTAP# Capsules 56 fallopian tube carcinoma 56 carotid artery thickness 56 VKORC1 56 PI3K Akt 56 myopathy rhabdomyolysis 56 extramedullary 56 interobserver 56 duplex ultrasonography 56 CD4 + CD# 56 myelofibrosis polycythemia vera 56 seminal vesicles 56 hepatic enzymes 56 conventional angiography 56 humanized monoclonal 56 extensive metabolizers 56 prespecified 56 nodal dissection 56 deoxy 56 rheumatoid factor 56 SSRI citalopram 56 Pegylated Liposomal Doxorubicin 56 morphologic 56 physiologically relevant 56 breast pancreatic 56 mg TID 56 cetuximab Erbitux R 56 diagnostic biomarker 56 gastrointestinal stromal tumors 56 μg liter 56 prostate biopsy 56 thymoma 56 histological diagnosis 56 MTHFR 56 flow cytometric 56 axillary nodes 56 highest tertile 56 favorable pharmacokinetic profile 56 CEACAM1 56 CIN3 56 malignant growths 56 hypermethylated 56 IGF IR 56 poor metabolizers 56 axillary lymph node 56 CD# expression [002] 56 labetuzumab 56 transesophageal echocardiography 56 Cytogenetic 56 adenoma 56 resectable pancreatic cancer 56 Prenatal diagnosis 56 hematoxylin 56 IOP lowering 56 neuroblastoma tumors 56 thromboembolic 56 proteomic analysis 56 decitabine 56 bone scintigraphy 56 RNAi therapeutic targeting PCSK9 56 cyclin dependent kinase inhibitor 56 UGT#A# * 56 EGFR mutation 56 CpG rich 56 5 HT4 receptor 56 mg BID dose 56 #p# [003] 56 Secondary endpoints include 56 papillary carcinoma 56 Cervista HPV HR 56 PCA3 gene 56 chemoembolization 56 squamous cell carcinoma SCC 56 intracoronary 56 non squamous NSCLC 56 cyclooxygenase COX 56 ABL1 56 obstructive coronary artery 56 neratinib 56 HER2 overexpression 56 Subgroup analyzes 56 serum PTH 56 Thalomid ® 56 Supplemental Figure 56 teriflunomide 56 ZACTIMA 56 erlotinib Tarceva ® 56 HLA DQ2 56 Gastrointestinal Stromal Tumors 56 BRAF V#E mutation 56 BRCA2 mutation carriers 56 serine protease inhibitor 56 mucosal lesions 56 allogeneic stem cell 56 5 HT2C receptor 56 fludarabine cyclophosphamide 56 substantially excreted 56 Tesmilifene 56 glutamic acid decarboxylase 56 clinico pathological 56 immunoreactive 56 HBeAg 56 HER2 negative 56 urodynamic parameters 56 Stent thrombosis 56 LV ejection fraction 56 serum antibody 56 Apoptone 56 sentinel lymph node biopsy 56 Apolipoprotein B 56 thromboxane A2 55 QTc prolongation 55 GH deficiency 55 Irinotecan 55 nondiagnostic 55 colorectal neoplasms 55 #ng/ml 55 docetaxel Taxotere ® 55 DAS# remission 55 atypical hyperplasia 55 syngeneic 55 molecular biomarkers 55 HBeAg negative patients 55 periventricular 55 r2 = 55 platelet reactivity 55 MBq 55 estramustine 55 Heterozygous 55 antiarrhythmic 55 p = NS 55 ductal cancer 55 nephron sparing surgery 55 antitrypsin 55 antiangiogenic 55 revascularization procedures 55 osteoblast 55 PNH patients 55 papillomas 55 GSTP1 55 ventricular myocardium 55 relapsed refractory 55 antiplatelet drugs 55 liver metastases 55 idiopathic myelofibrosis 55 cytoreduction 55 g mL 55 gadolinium enhanced 55 diabetes mellitus DM 55 interferon alfa 2b 55 NPM1 55 SCr 55 VeriStrat 55 lenalidomide dexamethasone 55 thymidylate synthase TS 55 grade gliomas 55 vinca alkaloid 55 univariate 55 nab paclitaxel 55 pmol 55 hyperacute 55 tonsillar 55 lymphomas leukemias 55 nmol 55 lymphocytic 55 malignant neoplasm 55 KRAS mutations occur 55 pelvic lymphadenectomy 55 serum retinol 55 transvaginal sonography 55 QT QTc 55 Alkaline Phosphatase 55 Sentinel Lymph Node Biopsy 55 JAK1 55 viral tropism 55 BRAF mutations 55 transferrin saturation 55 Adjuvant Treatment 55 daunorubicin 55 doxorubicin cyclophosphamide 55 recurrent GBM 55 paraganglioma 55 malignant ovarian 55 essential thrombocythemia ET 55 embryonic lethality 55 BRCA1 mutation carriers 55 Anticalins ® 55 Poly ICLC 55 sonographic 55 HGS ETR2 55 symptomatic intracranial hemorrhage 55 osteochondroma 55 P ≤ 55 non metastatic osteosarcoma 55 viral kinetics 55 HES CEL 55 GOUT 55 hyperhomocysteinemia 55 RAPAFLO R 55 nomograms 55 hepatic arterial 55 mutational status 55 Neoadjuvant 55 Elitek 55 LB# [003] 55 anaplastic 55 Supplementary Table 55 echogenicity 55 ProstaScint 55 virologic responses 55 prolonged QT interval